» Articles » PMID: 28058292

Monoclonal Antibodies That Recognize Various Folding States of Pure Human Butyrylcholinesterase Can Immunopurify Butyrylcholinesterase from Human Plasma Stored at Elevated Temperatures

Overview
Journal ACS Omega
Specialty Chemistry
Date 2017 Jan 7
PMID 28058292
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Human plasma to be analyzed for exposure to cholinesterase inhibitors is stored at 4 °C or lower to prevent denaturation of human butyrylcholinesterase (HuBChE), the biomarker of exposure. Currently published protocols immunopurify HuBChE using antibodies that bind native HuBChE before analysis by mass spectrometry. It is anticipated that the plasma collected from human casualties may be stored nonideally at elevated temperatures of up to 45 °C for days or maybe weeks. At 45 °C, the plasma loses 50% of its HuBChE activity in 8 days and 95% in 40 days. Our goal was to identify a set of monoclonal antibodies that could be used to immunopurify HuBChE from plasma stored at 45 °C. The folding states of pure human HuBChE stored at 4 and 45 °C and boiled at 100 °C were visualized on nondenaturing gels stained with Coomassie blue. Fully active pure HuBChE tetramers had a single band, but pure HuBChE stored at 45 °C had four bands, representing native, partly unfolded, aggregated, and completely denatured, boiled tetramers. The previously described monoclonal B2 18-5 captured native, partly unfolded, and aggregated HuBChE tetramers, whereas a new monoclonal, C191 developed in our laboratory, was found to selectively capture completely denatured, boiled HuBChE. The highest quantity of HuBChE protein was extracted from 45 °C heat-denatured human plasma when HuBChE was immunopurified with a combination of monoclonals B2 18-5 and C191. Using a mixture of these two antibodies in future emergency response assays may increase the capability to confirm exposure to cholinesterase inhibitors.

Citing Articles

Butyrylcholinesterase in SH-SY5Y human neuroblastoma cells.

Onder S, Schopfer L, Jiang W, Tacal O, Lockridge O Neurotoxicology. 2022; 90:1-9.

PMID: 35189179 PMC: 9124689. DOI: 10.1016/j.neuro.2022.02.006.


Delipidation of Plasma Has Minimal Effects on Human Butyrylcholinesterase.

Onder S, Tacal O, Lockridge O Front Pharmacol. 2018; 9:117.

PMID: 29497381 PMC: 5818420. DOI: 10.3389/fphar.2018.00117.

References
1.
Mrvova K, Obzerova L, Girard E, Krejci E, Hrabovska A . Monoclonal antibodies to mouse butyrylcholinesterase. Chem Biol Interact. 2012; 203(1):348-53. DOI: 10.1016/j.cbi.2012.10.007. View

2.
Schopfer L, Lockridge O, Brimijoin S . Pure human butyrylcholinesterase hydrolyzes octanoyl ghrelin to desacyl ghrelin. Gen Comp Endocrinol. 2015; 224:61-8. DOI: 10.1016/j.ygcen.2015.05.017. View

3.
Brimijoin S, Mintz K, Alley M . Production and characterization of separate monoclonal antibodies to human acetylcholinesterase and butyrylcholinesterase. Mol Pharmacol. 1983; 24(3):513-20. View

4.
Peng H, Brimijoin S, Hrabovska A, Krejci E, Blake T, Johnson R . Monoclonal antibodies to human butyrylcholinesterase reactive with butyrylcholinesterase in animal plasma. Chem Biol Interact. 2015; 243:82-90. PMC: 5097833. DOI: 10.1016/j.cbi.2015.11.011. View

5.
Gaydess A, Duysen E, Li Y, Gilman V, Kabanov A, Lockridge O . Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. Chem Biol Interact. 2010; 187(1-3):295-8. PMC: 2998607. DOI: 10.1016/j.cbi.2010.01.005. View